Jasper Therapeutics (NASDAQ:JSPR) Releases Earnings Results, Misses Expectations By $0.12 EPS

Jasper Therapeutics (NASDAQ:JSPR) posted its quarterly earnings data on Monday. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.12), Zacks reports.

Jasper Therapeutics Stock Up 0.3%

Shares of Jasper Therapeutics stock traded up $0.01 during trading on Monday, reaching $1.79. The company’s stock had a trading volume of 260,317 shares, compared to its average volume of 465,698. The business’s 50-day moving average price is $2.41 and its 200-day moving average price is $3.66. Jasper Therapeutics has a 52 week low of $1.60 and a 52 week high of $26.05. The firm has a market cap of $29.01 million, a PE ratio of -0.30 and a beta of 2.83.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on JSPR. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. BTIG Research cut their price target on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating for the company in a report on Monday, September 22nd. JMP Securities decreased their price objective on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a report on Monday, September 22nd. Evercore ISI dropped their price objective on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, September 22nd. Finally, UBS Group reduced their target price on shares of Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a report on Friday, August 15th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $25.63.

Insider Buying and Selling at Jasper Therapeutics

In other Jasper Therapeutics news, Director Judith Anne Shizuru purchased 41,000 shares of the company’s stock in a transaction dated Monday, September 22nd. The stock was bought at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the completion of the transaction, the director owned 156,901 shares in the company, valued at approximately $381,269.43. This represents a 35.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Thomas G. Wiggans purchased 41,000 shares of Jasper Therapeutics stock in a transaction that occurred on Monday, September 22nd. The shares were bought at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the transaction, the director directly owned 41,000 shares of the company’s stock, valued at $99,630. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 143,000 shares of company stock worth $347,490 over the last quarter. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Jasper Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Jasper Therapeutics by 65.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,032,842 shares of the company’s stock worth $2,458,000 after buying an additional 408,245 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Jasper Therapeutics by 11.2% during the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after acquiring an additional 23,453 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Jasper Therapeutics in the second quarter worth about $738,000. JPMorgan Chase & Co. lifted its stake in shares of Jasper Therapeutics by 1,074.7% in the second quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock worth $361,000 after acquiring an additional 59,547 shares during the period. Finally, Marshall Wace LLP bought a new stake in Jasper Therapeutics in the second quarter valued at approximately $281,000. 79.85% of the stock is currently owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.